Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, No 6 Shuangyong Road, Nanning, Guangxi, 530021, People's Republic of China.
Guangxi Key Laboratory Base of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention, No 6 Shuangyong Road, Nanning, Guangxi, 530021, People's Republic of China.
Sci Rep. 2022 May 20;12(1):8513. doi: 10.1038/s41598-022-12249-7.
Predicting the chances mortality within 1 year in non-ischemic dilated cardiomyopathy patients can be very useful in clinical decision-making. This study has developed and validated a risk-prediction model for identifying factors contributing to mortality within 1 year in such patients. The predictive nomogram was constructed using a retrospective cohort study, with 615 of patients hospitalized in the First Affiliated Hospital of Guangxi Medical University between October 2012 and May 2020. A variety of factors, including presence of comorbidities, demographics, results of laboratory tests, echocardiography data, medication strategies, and instances of heart transplant or death were collected from electronic medical records and follow-up telephonic consultations. The least absolute shrinkage and selection operator and logistic regression analyses were used to identify the critical clinical factors for constructing the nomogram. Calibration, discrimination, and clinical usefulness of the predictive model were assessed using the calibration plot, C-index and decision curve analysis. Internal validation was assessed with bootstrapping validation. Among the patients from whom follow-up data were obtained, the incidence of an end event (deaths or heart transplantation within 1 year) was 171 cases per 1000 person-years (105 out of 615). The main predictors included in the nomogram were pulse pressure, red blood cell count, left ventricular end-diastolic dimension, levels of N-terminal pro b-type natriuretic peptide, medical history, in-hospital worsening heart failure, and use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. The model showed excellent discrimination with a C-index of 0.839 (95% CI 0.799-0.879), and the calibration curve demonstrated good agreement. The C-index of internal validation was 0.826, which demonstrated that the model was quite efficacious. A decision curve analysis confirmed that our nomogram was clinically useful. In this study, we have developed a nomogram that can predict the risk of death within 1 year in patients with non-ischemic dilated cardiomyopathy. This will be useful in the early identification of patients in the terminal stages for better individualized clinical decisions.
预测非缺血性扩张型心肌病患者 1 年内的死亡率对于临床决策非常有用。本研究旨在建立并验证一个预测模型,以识别导致此类患者 1 年内死亡的相关因素。该预测列线图基于回顾性队列研究构建,纳入 2012 年 10 月至 2020 年 5 月在广西医科大学第一附属医院住院的 615 例患者。通过电子病历和随访电话咨询收集了各种因素,包括合并症、人口统计学、实验室检查结果、超声心动图数据、药物治疗策略以及心脏移植或死亡的发生情况。使用最小绝对收缩和选择算子(LASSO)和逻辑回归分析来识别构建列线图的关键临床因素。使用校准图、C 指数和决策曲线分析评估预测模型的校准、区分度和临床实用性。通过 bootstrap 验证评估内部验证。在获得随访数据的患者中,1 年内发生终点事件(死亡或心脏移植)的发生率为 1000 人年 171 例(615 例中 105 例)。列线图中的主要预测因素包括脉压、红细胞计数、左心室舒张末期内径、N 末端 pro-B 型利钠肽水平、既往史、住院期间心力衰竭恶化以及血管紧张素转换酶抑制剂或血管紧张素 II 受体阻滞剂的使用。该模型的区分度很高,C 指数为 0.839(95%CI:0.799-0.879),校准曲线显示一致性良好。内部验证的 C 指数为 0.826,表明该模型非常有效。决策曲线分析证实我们的列线图具有临床实用性。本研究建立了一种预测非缺血性扩张型心肌病患者 1 年内死亡风险的列线图,有助于早期识别终末期患者,从而更好地进行个体化临床决策。